Literature DB >> 18371557

Cardiorenal interactions: insights from the ESCAPE trial.

Anju Nohria1, Vic Hasselblad, Amanda Stebbins, Daniel F Pauly, Gregg C Fonarow, Monica Shah, Clyde W Yancy, Robert M Califf, Lynne W Stevenson, James A Hill.   

Abstract

OBJECTIVES: We examined the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) database to understand the impact and pathophysiology of renal dysfunction in patients hospitalized with advanced decompensated heart failure (HF).
BACKGROUND: Baseline renal insufficiency (RI) (estimated glomerular filtration rate [eGFR] <60 ml/min) and worsening renal function (WRF) (upward arrow serum creatinine [SCr] >or=0.3 mg/dl) during treatment of decompensated HF are associated with adverse outcomes.
METHODS: We used a Cox proportional hazards model to evaluate the impact of renal function on 6-month outcomes. Renal parameters were correlated with hemodynamic measurements. The impact of a strategy using pulmonary artery catheter (PAC) guidance on WRF and outcomes in patients with baseline RI was compared with treatment based on clinical assessment alone.
RESULTS: Baseline and discharge RI, but not WRF, were associated with an increased risk of death and death or rehospitalization. Among the hemodynamic parameters measured in patients randomized to the PAC arm (n = 194), only right atrial pressure correlated weakly with baseline SCr (r = 0.165, p = 0.03). There was no correlation between baseline hemodynamics or change in hemodynamics and WRF. A PAC-guided strategy was associated with less average increase in creatinine but did not decrease the incidence of defined WRF during hospitalization or affect renal function after discharge relative to clinical assessment alone.
CONCLUSIONS: Among patients with advanced decompensated HF, baseline RI impacts outcomes more than WRF. Poor forward flow alone does not appear to account for the development of RI or WRF in these patients. The addition of hemodynamic monitoring to clinical assessment does not prevent WRF or improve renal function after discharge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371557     DOI: 10.1016/j.jacc.2007.08.072

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  162 in total

1.  Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions.

Authors:  Jeffrey M Testani; Brian D McCauley; Jennifer Chen; Michael Shumski; Richard P Shannon
Journal:  Cardiology       Date:  2010-08-03       Impact factor: 1.869

2.  The conundrum of worsening renal function and optimal volume status in patients with acute decompensated heart failure.

Authors:  Theo E Meyer; Jeffrey Shih
Journal:  Curr Heart Fail Rep       Date:  2010-12

3.  Management of the cardiorenal syndrome in acute heart failure.

Authors:  Valentina Lazzarini; G Michael Felker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 4.  Pathophysiology and clinical evaluation of acute heart failure.

Authors:  Robert J Mentz; Christopher M O'Connor
Journal:  Nat Rev Cardiol       Date:  2015-09-15       Impact factor: 32.419

Review 5.  Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure.

Authors:  Christos V Bourantas; Huan P Loh; Nasser Sherwi; Ann C Tweddel; Ramesh de Silva; Elena I Lukaschuk; Antony Nicholson; Alan S Rigby; Simon D Thackray; Duncan F Ettles; Nikolay P Nikitin; Andrew L Clark; John G F Cleland
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

6.  Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.

Authors:  Toru Niwa; Katsuhisa Waseda; Tomofumi Mizuno; Yusuke Nakano; Kentaro Mukai; Hirokazu Wakabayashi; Atsushi Watanabe; Hirohiko Ando; Hiroaki Takashima; Tetsuya Amano
Journal:  J Echocardiogr       Date:  2017-02-13

7.  Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.

Authors:  Wendy McCallum; Hocine Tighiouart; Elaine Ku; Deeb Salem; Mark J Sarnak
Journal:  Kidney Int       Date:  2019-06-11       Impact factor: 10.612

Review 8.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

Review 9.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

Review 10.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.